Feier Catalin Vladut Ionut, Muntean Calin, Bolboacă Sorana D, Olariu Sorin
First Discipline of Surgery, Department X-Surgery, "Victor Babeș" University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timisoara, Romania.
First Surgery Clinic, "Pius Brinzeu" Clinical Emergency Hospital, 300723 Timisoara, Romania.
Diseases. 2024 Mar 20;12(3):61. doi: 10.3390/diseases12030061.
In light of the elevated incidence and consequential prognostic implications associated with colorectal cancer, a comprehensive investigation into the impact exerted by inflammatory status on patient management becomes imperative. A retrospective study spanning 7 years was conducted, involving the retrospective collection of data on colorectal cancer patients undergoing surgical intervention. We evaluated six inflammation ratios derived from complete peripheral blood counts. A thorough analysis of these markers' prognostic capacity was conducted, revealing that patients who died postoperatively displayed significantly higher preoperative Aggregate Index of Systemic Inflammation-AISI ( = 0.014) and Systemic Inflammation Response Index-SII ( = 0.0197) levels compared to those with successful discharge. Noteworthy variations in neutrophil-to-lymphocyte ratio ( = 0.0103), platelet-to-lymphocyte ratio ( = 0.0041), AISI ( < 0.001), and SII ( = 0.0045) were observed in patients necessitating postoperative Intensive Care Unit (ICU) monitoring. Furthermore, patients with complications, such as an intestinal fistula, exhibited significantly elevated AISI ( = 0.0489). Inflammatory biomarkers stand out as valuable prognostic tools for colorectal cancer patients, offering potential assistance in predicting their prognosis.
鉴于结直肠癌的发病率升高及其对预后的影响,对炎症状态对患者管理的影响进行全面调查变得势在必行。我们进行了一项为期7年的回顾性研究,回顾性收集接受手术干预的结直肠癌患者的数据。我们评估了从全血细胞计数得出的六个炎症比率。对这些标志物的预后能力进行了深入分析,结果显示,术后死亡的患者术前全身炎症综合指数(AISI,P = 0.014)和全身炎症反应指数(SII,P = 0.0197)水平显著高于成功出院的患者。在需要术后重症监护病房(ICU)监测的患者中,中性粒细胞与淋巴细胞比率(P = 0.0103)、血小板与淋巴细胞比率(P = 0.0041)、AISI(P < 0.001)和SII(P = 0.0045)存在显著差异。此外,出现肠瘘等并发症的患者AISI显著升高(P = 0.0489)。炎症生物标志物是结直肠癌患者有价值的预后工具,可为预测其预后提供潜在帮助。